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Dapsone is a commonly used second line drug for prophylaxis of pneumocystis jirovecii pneumonia (PJP) in
immunocompromised patients. Oxidant hemolysis, caused by dapsone’s metabolite hydroxylamine, is a common
side effect, and screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency is recommended before the
drug is started in order to prevent potential hemolytic reactions. We report a case of dapsone induced hemolytic
anemia in a patient with ANCA associated glomerulonephritis and normal G6PD level. Her anemia improved after
cessation of therapy with dapsone. We review the literature of dapsone induced hemolysis in patients who have
normal G6PD level and discuss potential pathways leading to hemolytic anemia and its implications for clinical practice.Introduction
Pneumocystis jirovecii pneumonia (PJP) is a common in-
fectious complication in immunocompromised patients
including HIV patients and organ transplant recipients.
Immunosuppressive drug treatment is used to induce re-
mission in patients with ANCA associated vasculitis
(AAV). The ANCA associated vasculitides include granu-
lomatosis with polyangiitis, microscopic polyangiitis and
eosinophilic granulomatosis with polyangiitis. The re-
ported rate of PJP in immunocompromised AAV patients
ranges from 1% to 20% (Guillevin et al. 1997; Ognibene
et al. 1995; Reinhold-Keller et al. 2000). Although there
are no randomized controlled trials, data from case series
and observational data from trials support the use of PJP
prophylaxis due to high mortality associated with PJP. The
current European League against Rheumatism (EULAR)
recommends the use of PJP prophylaxis for the manage-
ment of vasculitis (Mukhtyar et al. 2009).
Dapsone has been shown to be effective for PJP
prophylaxis for HIV patients in at least 41 clinical trials
of HIV patients (Hughes 1998). Dapsone is a commonly
used alternative for prophylaxis of pneumocystis jerovicci* Correspondence: gduvura@jhmi.edu
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in any medium, provided the original work is ppneumonia (PJP) in immunocompromised patients who
are intolerant to trimethoprim and sulfamethoxazole
(Hughes 1998). Oxidant hemolysis caused by its metabol-
ite hydroxylamine is a reported side effect in patients with
glucose-6-phosphate dehydrogenase (G6PD) deficiency
and therefore screening for G6PD deficiency is recom-
mended before the drug is started. Although dapsone in-
duced hemolytic anemia is mostly reported in patients
with G6PD deficiency, there are reports of dapsone in-
duced hemolytic anemia in literature regarding transplant
recipients who have normal G6PD levels (Lee et al. 2005;
Naik et al. 2008; Olteanu et al. 2012). Dapsone is also
often used for PJP prophylaxis in patients with AAV who
receive immunosuppressive drug therapy to induce remis-
sion. We report the first case of dapsone induced
hemolytic anemia in a patient with AAV in the setting of a
normal G6PD level. We provide a literature review of dap-
sone induced hemolysis in patients who have normal
G6PD level and discuss potential pathways leading to
hemolytic anemia in this setting and its implications for
patient care.Case report
A 60 year old Caucasian female was diagnosed with
ANCA associated vasculitis in October, 2013 when sheis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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2.4 mg/dl, hematuria and proteinuria with MPO ANCA
positivity, and a renal biopsy revealing pauci-immune
necrotizing and crescentic glomerulonephritis. She was
initially treated with oral cyclophosphamide and prednis-
one and after one month, her cyclophosphamide was
stopped and she was given rituximab for remission in-
duction. Due to her renal insufficiency, she was started
on dapsone for pneumocystis jirovecii pneumonia
prophylaxis after confirmation of normal glucose-6-
phosphate dehydrogenase (G6PD) activity level by quan-
titative testing twice. Her serum creatinine peaked at
3.1 mg/dl and improved to 2.16 mg/dl with immunosup-
pressive therapy. Her hemoglobin prior to initiation of
dapsone was 11.1. About a month later, her hemoglobin
was noted on routine labs to be 7.3 with an elevated
MCV of 104 and elevated corrected reticulocyte count
of 11.3%. She had normal iron stores, serum B12 and
folate levels. Her haptoglobulin was less than 7. Her dap-
sone was stopped with improvement in her hemoglobin
to 8.1, five days post discontinuation of dapsone therapy.
Discussion
We report the first case of dapsone induced hemolysis
in the setting of a normal G6PD level in a patient with
ANCA associated vasculitis which improved after dap-
sone was discontinued. We speculate that the severe
renal dysfunction in our patient could have led to high
dapsone blood level predisposing to hemolysis despite
the presence of normal G6PD activity level. This case
highlights the need for close clinical follow up in high
risk patients.
G6PD deficiency is one of the most common genetic
disorders of red blood cells worldwide with an estimated
400 million people carrying a mutation of the gene that
causes G6PD deficiency. The red blood cells depend
upon an adequate supply of reduced glutathione which
helps to detoxify hydrogen peroxide and other reactive
oxygen species. The role of G6PD in red blood cells is to
provide NADPH and maintain an adequate supply of re-
duced glutathione (Mason et al. 2007). When there is a
deficiency of G6PD and red blood cells are exposed to
oxidative challenge such as exposure to medications like
dapsone, the glutathione stores are rapidly exhausted
and as a result reactive oxygen species are not detoxified
(Beutler et al. 1957). This results in attack of sulfhydrylTable 1 Summary of studies of dapsone induced hemolytic an
Ref Number of
subjects
Clinical setting Dapsone dose
6 11 Solid organ transplant 100 mg
7 10 Lung transplant 100 mg
8 26 Stem cell transplant 100 mggroups in hemoglobin which causes damage to the cell
membrane, formation of Heinz bodies, and eventually
the destruction of red cells (Fischer et al. 1985; Luzzatto
and Seneca 2014).
Dapsone induced hemolysis occurs in approximately
4% of HIV patients receiving dapsone for PJP prophy-
laxis (Hughes 1998). In the setting of solid organ trans-
plant, the incidence of dapsone induced hemolytic
anemia in patients with normal G6PD level ranges from
23 % to 76% (Lee et al. 2005; Naik et al. 2008). In SCT
recipients, the incidence of hemolysis is 87% (Olteanu
et al. 2012). Anemia caused by dapsone induced hemolysis
can be mild and asymptomatic or severe requiring blood
transfusion. We summarize the data from these case series
in Table 1.
Lee et al. reported 11 cases of dapsone induced
hemolytic anemia in recipients of solid organ transplants
(3 kidney, 2 liver, 2 heart, 1 lung, 1 kidney and liver, 1
heart and kidney, 1 heart and lung) (Lee et al. 2005).
There were 6 male patients and 9 were Caucasian.
Hemolysis was defined as a decrease in hemoglobin with
presence of at least one laboratory marker of hemolysis
and an improvement to baseline hemoglobin after dis-
continuation of dapsone. Only six patients had G6PD
level checked prior to treatment and all six patients had
normal levels. The mean decrease in hemoglobin was
2.5 g/dL. Four patients required transfusion of packed
red blood cells. The majority of these patients were on
tacrolimus based immunosuppression. It was postulated
that elevated dapsone blood levels caused by concurrent
therapy with tacrolimus due to sharing of the cyto-
chrome P-450 isoenzyme for metabolism by these drugs
may have predisposed to hemolysis.
A retrospective review of 43 lung transplant recipients
by Naik et al. identified ten patients with dapsone in-
duced hemolytic anemia defined as low serum haptoglo-
bulin with simultaneous decrease in hemoglobin (Naik
et al. 2008). Of the 10 patients, 9 were tested for G6PD
activity and had normal G6PD level. Nine patients were
Caucasian and 7 were females. Mean drop in hemoglobin
was 2.7 g/dL. Peak serum creatinine ranged from 0.8 to
4.1 mg/dl. Patients with increased serum creatinine and
lower body weight were at higher risk of hemolysis sug-
gesting that dose adjustment for dapsone may be needed
in patients with renal insufficiency and lower body







6 23 (7–735) 4
9 83 (46–156) 7
26 13(7–36) NA
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cell transplants and normal G6PD level treated with
dapsone for PJP prophylaxis identified 26 cases of dap-
sone induced hemolysis (Olteanu et al. 2012). In this
series, the hemolysis, defined by a peripheral blood
smear evidence of bite cells and eccentrocytes, was mild
and patients were continued on dapsone with no adverse
consequences.
The occurrence of hemolysis in patients with normal
G6PD level suggest that the hemolysis may be a dose re-
lated event as may be seen with elevated dapsone levels
in patients with renal dysfunction or due to concurrent
use of medications that use the cytochrome P-450 iso-
enzyme system. Alternatively, there may be mutations
in hexose monophosphate shunt or glutathione metab-
olism that lead to glutathione depletion and subsequent
hemolysis.
Conclusion
In patients with renal dysfunction, lower body weight or
use of concurrent medications that interact with dap-
sone, we propose that regular monitoring of hemoglobin
should be done after initiation of dapsone even if G6PD
level is normal.
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